Phase 2 N=135 Clinical Trial of the "Living Well With Hearing Loss Workshop"
Hearing Loss · Stress
Primary: Communication Profile for Hearing Impaired: Maladaptive Strategies Subscale — 0.33; 0.37 score on a scale — p=0.69
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 Does Nesiritide Provide Renal Protection
Renal Failure
Primary: Measure Neutrophils to Measure Kidney Injury — 5.453; 5.630; 4.508; 4.546 log2 expression
Phase 1 N=24 Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers
Asthma
Primary: Incidence of Adverse Events — 5; 4; 6; 2 Participants
N/A N=142 Growth Hormone, Cardiovascular Risk, and Visceral Adiposity
Obesity
Primary: HsCRP — -1.1; 0.5; -1.3; -0.3 mg/L
Phase 1 N=2 Enhancing Participation In the Community by Improving Wheelchair Skills: Phase 2
Older Adult Manual Wheelchair Users
Primary: Change From Baseline in Wheelchair Skills Test (WST) 4.1 Capacity Score — 6.25 units on a scale
Phase 2 N=24 Tolcapone Treatment of Pathological Gambling
Pathological Gambling
Primary: Clinical Global Impression Scale (CGI) — 2.88 units on a scale
Phase 4 N=491 PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia
Schizophrenia
Primary: Percentage of Participants Assessed as Very Much Improved or Much Improved Based on Clinical Global Impression-Improvement (CGI-I) Scale - Intent-to-treat (ITT)…
Phase 4 N=32 Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons
HSV Infection · HIV Infection
Primary: Mean Level of HIV-1 RNA in Plasma of Participants While on Acyclovir or Valacyclovir. — 3.56; 2.94 log10 copies/mL
Phase 3 N=281 A Study in Pediatric Participants With Generalized Anxiety Disorder
Anxiety Neuroses · Anxiety States, Neurotic · Neuroses, Anxiety
Primary: Change From Baseline to 10-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety…
Phase 4 N=1,034 Evaluation of National Cancer Institute (NCI) Smoking Intervention Resources
Smoking Cessation · Smoking · Nicotine Dependence
Primary: 7-Day Point-Prevalence Abstinence From Smoking — 27.8; 26.3; 30.5; 23.4 percentage of participants not smoking — p=.825
N/A N=51 X-ray Dose Reduction Study for Endovascular Interventional Radiology
Cardiovascular Disease
Primary: Image Quality — 0.96 Proportion of images rated equal/better
Phase 3 N=130 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Cancer
Primary: Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30) — 640.3; 399.6 Units on a scale
Phase 2 N=111 Family History Study of Alcohol Consumption Using Memantine
Alcohol Drinking
Primary: Number of Drinks Consumed on Day 7 — 5.84; 5.61; 6.21 standard drinks
N/A N=389 Long-term Control in Rhinosinusitis After Functional Endoscopic Sinus Surgery (FESS)
Condition of Patient 3 Years After FESS-operation
Primary: Control Status of Patients With Rhinosinusitis — 19.5; 36.8; 43.7 percentage of participants
N/A N=35 Mellow Bumps RCT - Antenatal Intervention for Vulnerable Women
Mental Health Wellness 1 · Pregnancy · Mother-Child Relations
Primary: Anxiety, Depression and Irritability Measured on Adult Wellbeing Scale — 6.57; 4.67; 5.50; 5.29 Scores on a scale